Recent 8-K filings for MAZE

• May 12, 2026, 4:07 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial

  MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.

• April 22, 2026, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Maze Therapeutics prices $150M registered offering; net proceeds ~$144.7M

  Offering of 5,540,000 shares at $23.50/share and 850,000 pre-funded warrants at $23.499 each.

• March 25, 2026, 7:59 PM ET other material materiality 0.80 positive item 2.02item 5.02item 7.01item 9.01 ◈ Earnings Releases

  Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board

  Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.

• February 4, 2026, 6:59 PM ET debt materiality 0.70 neutral item 1.01item 1.02item 2.03 ◈ Debt Financings◈ Material Agreements

  Maze Therapeutics enters $200M Hercules Capital term loan facility; initial $40M funded

  Up to $200M senior secured term loan from Hercules Capital; initial $40M (Tranche 1A) funded Feb 4, 2026.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026

  Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.

• October 6, 2025, 7:59 PM ET leadership materiality 0.60 positive item 5.02

  Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6

  Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.

• September 11, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 3.02item 7.01item 9.01 ◈ Equity Issuances ×2

  Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026

  Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.

• September 2, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Maze Therapeutics appoints Misbah Tahir as CFO, effective Sep 2, 2025

  Misbah Tahir appointed CFO, previously CFO of IGM Biosciences (Jan 2019–Aug 2025).

• August 12, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M

  Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).

• May 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated

  Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.

• March 31, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Maze Therapeutics: Q4 net loss $29.6M, FY net income $52.2M on $167.5M license revenue; cash runway into H2 2027

  Q4 net loss $29.6M vs $26.6M loss a year ago; FY net income $52.2M vs $100.4M loss in 2023.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

5 positive 1 negative 7 neutral

source · MAZE on sec.gov